Business
AC Immune Announces Upcoming Industry Symposium on Parkinson’s Disease and Presentation at AD/PD™ 2026
AC Immune Announces Upcoming Industry Symposium on Parkinson’s Disease and Presentation at AD/PD™ 2026 AC Immune to host symposium highlighting Precision
About this update from Ac Immune Sa
[{"type":"text","content":"AC Immune Announces Upcoming Industry Symposium on Parkinson’s Disease and Presentation at AD/PD™ 2026 AC Immune to host symposium highlighting Precision Prevention approach to Parkinson's diseasePresentation at International Conference on Alzheimer’s and Parkinson’s Disease (AD/PD™ 2026) showcases potential of first-in-class TDP-43 PET-tracer ACI-19626 Lausanne, Switzerland, March 5, 2026 -- AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision therapeutics for neurodegenerative diseases, today announced it will host an industry symposium on how a precision prevention approach to Parkinson’s disease may now be within reach, based on lessons from Alzheimer’s disease. AC Immune will also present its first-in-class TDP-43 PET-tracer on ACI-19626 at the International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PD™ 2026) taking place in Copenhagen, Denmark, on March 17-21, 2026. Industry Symposium: From Treatment to Prevention in Parkinson’s Disease Session Date/Time: Wednesday, March 18, 2026, 8:40 – 10:40 am CETLocation: Hall A1 Opening and Closing Remarks: Andrea Pfeifer, Ph.D., CEO of AC ImmuneShifting treatment to prevention: lessons learned from Alzheimer’s disease Presenter: Prof. Catherine Mummery (University College London) Time: 8:45 – 9:00 am CET Targeting α-synuclein in Parkinson’s disease: pathophysiology and supporting evidence Presenter: Werner Poewe, M.D. (Medical University of Innsbruck)Time: 9:00 – 9:25 am CET Misfolding of α-synuclein as fluid biomarker measured with the iRS platform of betaSENSE Presenter: Prof. Klaus Gerwert (Centre for Protein Diagnostics at Ruhr University Bochum)Time: 9:25 – 9:40 am CET Stabilizing the progression of Parkinson’s disease with active immunotherapy: Interim results of the Phase 2 VacSYn trial of ACI-7104.056 Presenter: Günther Staffler, Ph.D. (AC Immune)Time: 9:40 – 10:05 am CET Intracellular targeting of α-synuclein with Morphomer small molecules Presenter: Francesca Capotosti, Ph.D. (AC Immune)Time: 10:05 – 10:20 am CET The presentations will be followed by a Q&A session, and a replay of the Industry Symposium will be available on the Events page of AC Immune’s website after the event. Oral Presentation Discovery and initial clinical evaluation of [18f]ACI-19626, a first-in-class TDP-43 PET-tracer Presenter: Tamara Seredenina, ...